An improved form of spinal cord stimulation (SCS) offers clinicians additional therapeutic options for chronic pain management, according to a press release from the developer. St. Jude Medical, Inc., has announced FDA approval of BurstDR Stimulation that is asserted to provide superior patient outcomes compared to other forms of SCS therapy. Allen Burton, MD, medical director of neuromodulation and vice president of medical affairs at St. Jude Medical, stated, “With FDA approval of BurstDR stimulation, we are empowering physicians with a new therapy option in their fight against widespread chronic pain.”
BurstDR stimulation differs from other forms of SCS in the utilization of intermittent pulses that are designed to simulate the body’s nature patterns of nerve impulse. The proprietary technology developed by St. Jude Medical is the only offering to have been evaluated in a large-scale randomized controlled clinical trial, according to the press release. The company states that trial results demonstrated that BurstDR stimulation offered superior pain relief, and was preferred by most patients, in comparison to traditional SCS therapy. The US based SUNBURST study confirms results obtained from other studies conducted internationally, according to the statement.
The press release may be read here.